Evidence map›Paper›PMID 35916354›Full record

ArticleESC heart failure2022

Ambulatory haemodynamic-guided management reduces heart failure hospitalizations in a multicentre European heart failure cohort.

Jeroen Dauw, Mateusz Sokolski, Jennifer T Middleton, Petra Nijst, Matthias Dupont, Omid Forouzan, Alexander M K Rothman, Frank Ruschitzka, Andreas J Flammer, Wilfried Mullens

Open access · goldAbstract readMulticenter Study
In one paragraph

Article in ESC heart failure, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
2.5field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 15 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Review
  5. Article
  6. High-intensity care for GDMT titration.Heart failure reviews · 2024
    Review
  7. Article
  8. Article
  9. Article
  10. Review
  11. Review
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 4 institutions in 4 countries.

Jeroen DauwDepartment of Cardiology, Ziekenhuis Oost-Limburg, Genk, Belgium.ORCID 0000-0003-4605-3450
Mateusz SokolskiUniversity Heart Center, University Hospital Zurich, Zurich, Switzerland.ORCID 0000-0001-9925-3566
Jennifer T MiddletonDepartment of Infection, Immunity and Cardiovascular Disease, University of Sheffield, Sheffield, UK.ORCID 0000-0003-4931-584X
Petra NijstDepartment of Cardiology, Ziekenhuis Oost-Limburg, Genk, Belgium.ORCID 0000-0002-7325-7734
Matthias DupontDepartment of Cardiology, Ziekenhuis Oost-Limburg, Genk, Belgium.ORCID 0000-0002-0802-9508
Omid ForouzanDepartment of Cardiology, Ziekenhuis Oost-Limburg, Genk, Belgium.ORCID 0000-0002-2382-1544
Alexander M K RothmanDepartment of Infection, Immunity and Cardiovascular Disease, University of Sheffield, Sheffield, UK.ORCID 0000-0002-7847-4500
Frank RuschitzkaUniversity Heart Center, University Hospital Zurich, Zurich, Switzerland.ORCID 0000-0001-5972-0596
Andreas J FlammerUniversity Heart Center, University Hospital Zurich, Zurich, Switzerland.ORCID 0000-0002-1373-0630
Wilfried MullensDepartment of Cardiology, Ziekenhuis Oost-Limburg, Genk, Belgium.ORCID 0000-0001-9995-8590
Ziekenhuis Oost-Limburg · BEUniversity Hospital of Zurich · CHUniversity of Sheffield · GBWroclaw Medical University · PL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

aimsTo investigate the outcomes and associated costs of haemodynamic-guided heart failure (HF) management with a pulmonary artery pressure (PAP) sensor in a multicentre European cohort. METHODS AND

resultsData from all consecutive patients receiving a PAP sensor in Ziekenhuis Oost-Limburg, University Hospital Zurich and Sheffield Teaching Hospitals NHS Foundation Trust before January 2021 were collected. Medication changes, total number of HF hospitalizations and HF related health care costs (composed of HF hospitalizations, outpatient cardiology visits and monitoring costs) were compared between the pre-implantation and post-implantation period at 3, 6, and 12 months. PAP evolution post-implantation were grouped according to baseline mPAP ≥25 mmHg versus <25 mmHg and changes from baseline were analyzed via an area under the curve (AUC) analysis. A total of 48 patients received a PAP sensor (29 CardioMEMS and 19 Cordella devices) with a median follow-up of 19 (13-30) months. Mean age was 71 ± 10 years, 25.0% were female, 68.8% had a left ventricular ejection fraction < 50%, median NT-proBNP was 1801 (827-4503) pg/mL, and 89.6% were in NYHA class III. The number of diuretic therapy changes were non-significantly increased after 3 months (49 vs. 82; P = 0.284) and 6 months (82 vs. 127; P = 0.093) with a significant increase noted after 12 months (118 vs. 195; P = 0.005). The mPAP AUC decreased by -1418 mmHg-days for patients with a baseline mean PAP ≥ 25 mmHg. The number of HF hospitalizations was reduced for all patients after 6 (34 vs. 17; P = 0.014) and 12 months (48 vs. 29; P = 0.032). HF related health care costs were reduced from € 6286 to € 3761 at 6 months (P = 0.012) and from € 8960 to € 6167 at 12 months (P = 0.032).

conclusionHaemodynamic-guided HF management reduces HF hospitalizations and HF related health care costs in selected HF patients amongst different European health care systems.

Indexed as

Heart FailureVentricular Function, LeftAgedAged, 80 and overFemaleHemodynamicsHospitalizationHumansMaleMiddle AgedStroke VolumeDiureticsHealth care costsHeart failurePulmonary artery pressure monitoringTelemonitoring

Identifiers

PMID35916354
PMCPMC9773754
OpenAlexW4289518239

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.